Semi-automated closed system manufacturing of lentivirus gene-modified haematopoietic stem cells for gene therapy

Abstract

Current methods for haematopoietic stem cell gene therapy are laborious and require special licensed facilities. Here the authors develop a semi-automated protocol using a commercially available device to allow for benchtop generation of gene-modified blood cell products for transplantation, that meet current standards.